Clinical Trial Update: Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating topical resiquimod for early stage cutaneous T cell lymphoma (CTCL) has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Resiquimod (resiquimod)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Cutaneous T Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-08-13